Nelotanserin, a novel selective human 5-hydroxytryptamine2A inverse agonist for the treatment of insomnia

Journal of Pharmacology and Experimental Therapeutics

Volumn 332, Issue 1, 2010, Pages 281-290

  Al Shamma, Hussien A ^a   Anderson, Christen ^a   Chuang, Emil ^a   Luthringer, Remy ^b   Grottick, Andrew J ^a   Hauser, Erin ^a   Morgan, Michael ^a   Shanahan, William ^a   Teegarden, Bradley R ^a   Thomsen, William J ^a   Behan, Dominic ^a  

^a ARENA PHARMACEUTICALS   (United States)

^b FORENAP   (France)

Author keywords

[No Author keywords available]

Indexed keywords

4 IODO 2,5 DIMETHOXYAMPHETAMINE; NELOTANSERIN; PLACEBO; SEROTONIN 2A AGONIST; SEROTONIN 2B RECEPTOR; SEROTONIN 2C RECEPTOR; UNCLASSIFIED DRUG;

ADULT; ANIMAL CELL; ANIMAL CELL CULTURE; ARTICLE; CELL STRAIN COS7; CELL STRAIN HEK293; CLINICAL TRIAL; CONCENTRATION RESPONSE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG STRUCTURE; DRUG SYNTHESIS; ELECTROENCEPHALOGRAM; EMBRYO; EYE MOVEMENT; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IN VITRO STUDY; IN VIVO STUDY; INSOMNIA; LIGAND BINDING; LOW DRUG DOSE; MALE; MEMORY; MORNING DOSAGE; NONHUMAN; PRIORITY JOURNAL; PSYCHOMOTOR PERFORMANCE; RANDOMIZED CONTROLLED TRIAL; RAT; REM SLEEP; REPEATED DRUG DOSE; SINGLE DRUG DOSE; SLEEP TIME; VOLUNTEER;

ADOLESCENT; ADULT; ANIMALS; CELL LINE; CELL MEMBRANE; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; HUMANS; LIGANDS; MALE; MIDDLE AGED; MOTOR ACTIVITY; PHENYLUREA COMPOUNDS; POLYSOMNOGRAPHY; PROTEIN BINDING; PYRAZOLES; RADIOLIGAND ASSAY; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, SEROTONIN, 5-HT2A; RECOMBINANT PROTEINS; SEROTONIN AGONISTS; SLEEP; SLEEP INITIATION AND MAINTENANCE DISORDERS; YOUNG ADULT;

EID: 73949098111     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.109.160994     Document Type: Article

References (37)

1. Abrams JK, Johnson PL, Hay-Schmidt A, Mikkelsen JD, Shekhar A, and Lowry CA (2005) Serotonergic systems associated with arousal and vigilance behaviours following administration of anxiogenic drugs. Neuroscience 133:983-997.
2. Borbély AA, Trachsel L, and Tobler I (1988) Effect of ritanserin on sleep stages and sleep EEG in the rat. Eur J Pharmacol 156:275-278.
3. 50) of an enzymatic reaction. Biochem Pharmacol 22:3099-3108.
4. Da Settimo F, Taliani S, Trincavelli ML, Montali M, and Martini C (2007) GABA A/Bz receptor subtypes as targets for selective drugs. Curr Med Chem 14:2680-2701.
5. Drover DR (2004) Comparative pharmacokinetics and pharmacodynamics of shortacting hypnosedatives: zaleplon, zolpidem and zopiclone. Clin Pharmacokinet 43: 227-238.
6. Dugovic C and Wauquier A (1987) 5-HT2 receptors could be primarily involved in the regulation of slow wave sleep in the rat. Eur J Pharmacol 137:145-146.
7. Dursun SM, Patel JK, Burke JG, and Reveley MA (1999) Effects of typical antipsychotic drugs and risperidone on the quality of sleep in patients with schizophrenia: a pilot study. J Psychiatry Neurosci 24:333-337.
8. 2A receptor by site-directed mutagenesis: inverse agonist activity of antipsychotic drugs. J Pharmacol Exp Ther 286:85-90.
9. 2A ligands for the treatment of insomnia. Bioorg Med Chem Lett 15:3665-3669.
10. Francon D, Decobert M, Herve B, Richard A, Griebel G, Avenet P, Scatton B, and Fur GL (2007) Eplivanserin promotes sleep maintenance in rats. Sleep Biol Rhythms 5:A3.
11. Frank MG, Stryker MP, and Tecott LH (2002) Sleep and sleep homeostasis in mice lacking the 5-HT2C receptor. Neuropsychopharmacology 27:869-873.
12. Hoyer D, Clarke DE, Fozard JR, Hartig PR, Martin GR, Mylecharane EJ, Saxena PR, and Humphrey PP (1994) International Union of Pharmacology classification of receptors for 5-hydroxytryptamine (serotonin). Pharmacol Rev 46:157-203.
13. Idzikowski C, Mills FJ, and Glennard R (1986) 5-Hydroxytryptamine-2 antagonist increases human slow wave sleep. Brain Res 378:164-168.
14. Kenakin T (2004) Efficacy as a vector: the relative prevalence and paucity of inverse agonism. Mol Pharmacol 65:2-11.
15. Krystal AD, Walsh JK, Laska E, Caron J, Amato DA, Wessel TC, and Roth T (2003) Sustained efficacy of eszopiclone over 6 months of nightly treatment: results of a randomized, double-blind, placebo controlled study in adults with chronic insomnia. Sleep 26:793-799.
16. Landolt HP, Meier V, Burgess HJ, Finelli LA, Cattelin F, Achermann P, and Borbély AA (1999) Serotonin-2 receptors and human sleep: effect of a selective antagonist on EEG power spectra. Neuropsychopharmacology 21:455-466.
17. Leysen JE (2004) 5-HT2 receptors. Curr Drug Targets CNS Neurol Disord 3:11-26.
18. Mathias S, Steiger A, and LancelM(2001) The GABA(A) agonist gaboxadol improves the quality of post-nap sleep. Psychopharmacology 157:299-304.
19. 2C receptor antagonists EMD 281014 and SB-243213, respectively, on sleep and waking in the rat. Eur J Pharmacol 553: 163-170.
20. Monti JM and Monti D (2004) Sleep in schizophrenia patients and the effects of antipsychotic drugs. Sleep Med Rev 8:133-148.
21. 6 receptor antagonists promote sleep in rats. Sleep 31:34-44.
22. Nicholson AN and Pascoe PA (1986) Hypnotic activity of an imidazo-pyridine (zolpidem). Br J Clin Pharmacol 21:205-211.
23. 2A receptors. J Neurosci 25:11231-11238.
24. Roth BL, Willins DL, Kristiansen K, and Kroeze WK (1998) 5-Hydroxytryptamine 2-family receptors (5-hydroxytryptamine 2A, 5-hydroxytryptamine 2B, 5-hydroxytryptamine 2C): where structure meets function. Pharmacol Ther 79:231-257.
25. Roth T, Roehrs T, and Pies R (2007) Insomnia: pathophysiology and implications for treatment. Sleep Med Rev 11:71-79.
26. Roth T, Walsh JK, Krystal A, Wessel T, and Roehrs TA (2005) An evaluation of the efficacy and safety of eszopiclone over 12 months in patients with chronic primary insomnia. Sleep Med 6:487-495.
27. Scharf MB, Roth T, Vogel GW, and Walsh JK (1994) A multicenter, placebocontrolled study evaluating zolpidem in the treatment of chronic insomnia. J Clin Psychiatry 55:192-199.
28. 2 receptor antagonists on slow wave sleep in humans. Psychopharmacology 101:568-569.
29. Sharpley AL, Vassallo CM, and Cowen PJ (2000) Olanzapine increases slow-wave sleep: evidence for blockade of central 5-HT2C receptors in vivo. Biol Psychiatry 47:468-470.
30. 2A inverse-agonists for the treatment of insomnia. Curr Top Med Chem 8:969-976.
31. Thomsen WJ, Grottick AJ, Menzaghi F, Reyes-Saldana H, Espitia S, Yuskin D, Whelan K, Martin M, Morgan M, Chen W, et al. (2008) Lorcaserin, a novel selective human 5-hydroxytryptamine 2C agonist: in vitro and in vivo pharmacological characterization. J Pharmacol Exp Ther 325:577-587.
32. Troy SM, Lucki I, Unruh MA, Cevallos WH, Leister CA, Martin PT, Furlan PM, and Mangano R (2000) Comparison of the effects of zaleplon, zolpidem, and triazolam on memory, learning, and psychomotor performance. J Clin Psychopharmacol 20:328-337.
33. 2A receptor inverse agonist. J Pharmacol Exp Ther 317:910-918.
34. Walsh JK, Vogel GW, Scharf M, Erman M, William Erwin C, Schweitzer PK, Mangano RM, and Roth T (2000) A five-week, polysomnographic assessment of zaleplon 10 mg for the treatment of primary insomnia. Sleep Med 1:41-49.
35. Wing LL, Tapson GS, and Geyer MA (1990) 5HT-2 mediation of acute behavioral effects of hallucinogens in rats. Psychopharmacology 100:417-425.
36. Yamashita H, Morinobu S, Yamawaki S, Horiguchi J, and Nagao M (2002) Effects of risperidone on sleep in schizophrenia: a comparison with haloperidol. Psychiatry Res 109:137-142.
37. Zammit GK, McNabb LJ, Caron J, Amato DA, and Roth T (2004) Efficacy and safety of eszopiclone across 6 weeks of treatment for primary insomnia. Curr Med Res Opin 20:1979-1991.